Mile High Labs


In October, Mile High Labs opened the doors of its new 400,000-square-foot facility in Broomfield, Colorado. The fully operational plant allows Mile High Labs to expand into the production of capsules, tablets, topicals and gummies, in addition to CBD isolate and distillate ingredients. The former pharmaceutical facility includes equipment and infrastructure for research and development, quality assurance, bottling, filling, packing, warehousing, labelling, shipping and compliance monitoring.

“This building will be the hub of innovation in the industry,” said Stephen Mueller, founder and CEO of Mile High Labs. “There is so much excitement surrounding hemp and cannabinoids. We hope this facility will spur other companies to collaborate and innovate in Colorado and create a cluster of cannabinoid innovation.”

The new facility will allow the company to scale and improve their industry-leading global distribution of CBD ingredients and finished products. Along with labs in Loveland and Broomfield, Colorado, Mile High Labs has offices and distribution centres in London and Belfast.

The European operation has enjoyed a period of rapid growth since it opened its European Headquarters in Belfast, Northern Ireland in March 2019. From a standing start, the company now employs 24 staff, with 15 based at the Belfast office and nine in London. The company, which began in 2016 with just one employee and now employs over 200 in Colorado, is seen across the CBD sector as a “best in class” proponent for better regulation, high standards of manufacturing and consumer protection.

John Wallace, Managing Director and Head of Operations UK/EU at Mile High Labs International says the company is benefiting from a rapidly expanding market coupled with a growing reputation for quality and high manufacturing standards:

“We’re delighted to announce our expansion after our first six months of trading here in the UK. When we established our Belfast operation, we knew we had a quality product and that the market in the UK and Europe was growing. However, even we have been surprised by the speed of our growth both in terms of sales and in personnel. Our manufacturing processes, our investment in regulatory adherence and our industry changing levels of customer service are standing us in good stead, and I would like to personally thank those who have supported us in our formative times.”

CBD is the non-psychoactive element of the cannabis plant, while isolate refers to its purified form. CBD remains legal in the UK so long as it does not contain THC, the component which produces the cannabis “high.”

According to the Brightfield Group, the CBD market is projected to reach $22 billion by 2022. Market research commissioned by the Centre for Medicinal Cannabis in London estimates that the CBD market is currently one of the fastest growing wellbeing product categories in the UK. At the current rate it will be worth almost £1B per annum by 2025, equivalent in size to the current entire UK herbal supplement market.

A commitment to compliance, scalability and supply chain logistics makes Mile High Labs the premier CBD supplier of choice for worldwide brands.